search.noResults

search.searching

saml.title
dataCollection.invalidEmail
note.createNoteMessage

search.noResults

search.searching

orderForm.title

orderForm.productCode
orderForm.description
orderForm.quantity
orderForm.itemPrice
orderForm.price
orderForm.totalPrice
orderForm.deliveryDetails.billingAddress
orderForm.deliveryDetails.deliveryAddress
orderForm.noItems
,


New allergy medication Histallay (Fexofenadine Hydrochloride 120 mg tablets) now available over the counter from pharmacies across the UK


Dr. Reddy’s Laboratories (UK) Ltd has recently announced the launch of its new allergy medication Histallay into the UK General Sales List (GSL) market. Dr. Reddy’s is already one of the largest producers of Fexofenadine Hydrochloride (the active pharmaceutical ingredient in Histallay), the most dispensed antihistamine in the UK.


Dr. Reddy’s Fexofenadine 120 mg was previously classified as a Prescription Only Medicine (POM). With Histallay’s introduction, Dr. Reddy’s Fexofenadine 120 mg is now available without prescription, meaning people with allergic seasonal rhinitis (hayfever) have direct access to the product via retail outlets in the UK. Histallay is Dr. Reddy’s first GSL product in the UK market.


Around 10 million people in the UK suffer from seasonal allergies, and the number of people with hay fever symptoms is rising. 37% of people have reported developing symptoms for the first time in the past five years, according to a poll by Allergy UK.


Allergy sufferers want better options, according to Dr. Reddy’s recent research. On behalf of Dr. Reddy’s, Ipsos carried out 60-minute one-to- one qualitative interviews with 28 allergy sufferers aged 18 or older in the UK. A number of participants reported feeling anxious because of the unpredictability of their allergies, embarrassed in social settings, and go out of their way to avoid outdoor activities. “Hay fever is just such a waste of time. I feel like a loser,” said one male respondent with heavy allergy symptoms.


Kristine Oberte, Country Head UK of Dr. Reddy’s Laboratories, said: “Our expertise in the allergy sector has already allowed us to become a leader in the UK’s prescription fexofenadine market. By making Histallay available over the counter, we enable allergy sufferers to get faster access to treatment and better control over their symptoms since early treatment is key.”


Investment into promotion Dr. Reddy’s Laboratories is investing in a media and advertising plan with a 360° smart marketing mix to support pharmacies and supermarkets and drive consumer demand for Histallay.


Find out more at www.histallay.co.uk (Tel: 01223651475).


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48